Topic Editors

iBB-Institute for Bioengineering and Biosciences and i4HB-Institute for Health and Bioeconomy, Instituto Superior Técnico, Av. Rovisco Pais, 1049-001 Lisboa, Portugal
IBB—Institute for Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisboa, Portugal

Antimicrobial Agents and Nanomaterials—2nd Edition

Abstract submission deadline
31 October 2026
Manuscript submission deadline
31 December 2026
Viewed by
1743

Topic Information

Dear Colleagues,

Antimicrobial resistance (AMR) has come to represent a major problem that has been demonstrated across healthcare settings worldwide. AMR is caused by multidrug-resistant (MDR) microorganisms, or “superbugs”, which can evade many of the antibiotics used in clinical practice. Today, MDR microorganisms constitute a great clinical and economic burden. In fact, the current methods of clinical treatment have started to rely on more aggressive antibiotic therapy, leading to a decrease in the life quality of the infected patients and an increase in the associated therapeutic costs. Due to the failure of conventional antibiotics, we are now entering a new era of clinical treatment based on compounds. This is reflected, for example, in the development of antibacterial nanomaterials or nanoantibiotics. This Topic aims to identify the novel strategies that may be used to overcome AMR, with a particular focus on the development of medical nanomaterials. Topics of interest include, but are not limited to, the following:

  • Antimicrobial polymers;
  • Antimicrobial peptides and peptidomimetics;
  • Synergic effects of antimicrobial agents;
  • Antimicrobial coatings;
  • Inhibitors of virulence factors;
  • Drug nanodelivery systems.

We welcome the contributions of authors working in this critical field of research.

Prof. Dr. Vasco D. B. Bonifácio
Dr. Sandra Pinto
Topic Editors

Keywords

  • multidrug-resistant bacteria (MDR)
  • resistance mechanisms
  • antibiotics
  • novel antimicrobial agents
  • drug susceptibility

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
Biomolecules
biomolecules
4.8 9.2 2011 19.4 Days CHF 2700 Submit
International Journal of Molecular Sciences
ijms
4.9 9.0 2000 20.5 Days CHF 2900 Submit
Micro
micro
1.9 3.2 2021 28.1 Days CHF 1200 Submit
Molecules
molecules
4.6 8.6 1996 16.1 Days CHF 2700 Submit
Antibiotics
antibiotics
4.6 8.7 2012 15 Days CHF 2900 Submit
Nanomaterials
nanomaterials
4.3 9.2 2010 15.4 Days CHF 2400 Submit
Microorganisms
microorganisms
4.2 7.7 2013 15.2 Days CHF 2700 Submit
Journal of Functional Biomaterials
jfb
5.2 6.8 2010 15.9 Days CHF 2700 Submit

Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.

MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:

  1. Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
  2. Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
  3. Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
  4. Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
  5. Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (2 papers)

Order results
Result details
Journals
Select all
Export citation of selected articles as:
29 pages, 1391 KB  
Review
Nanocurcumin and Curcumin-Loaded Nanoparticles in Antimicrobial Photodynamic Therapy: Mechanisms and Emerging Applications
by Edith Dube and Grace Emily Okuthe
Micro 2025, 5(3), 39; https://doi.org/10.3390/micro5030039 - 18 Aug 2025
Viewed by 367
Abstract
The growing threat of antimicrobial resistance has necessitated the development of alternative, non-antibiotic therapies for effective microbial control. Antimicrobial photodynamic therapy, which uses photosensitizers activated by light to generate reactive oxygen species, offers a promising solution. Among natural photosensitizers, curcumin, a polyphenolic compound [...] Read more.
The growing threat of antimicrobial resistance has necessitated the development of alternative, non-antibiotic therapies for effective microbial control. Antimicrobial photodynamic therapy, which uses photosensitizers activated by light to generate reactive oxygen species, offers a promising solution. Among natural photosensitizers, curcumin, a polyphenolic compound from Curcuma longa, has demonstrated broad-spectrum antimicrobial activity through reactive oxygen species-mediated membrane disruption and intracellular damage. However, curcumin’s poor water solubility, low stability, and limited bioavailability hinder its clinical utility. Nanotechnology has emerged as a transformative strategy to overcome these limitations. This review comprehensively explores advances in nanocurcumin- and curcumin-loaded nanoparticles, highlighting their physicochemical enhancements, photodynamic mechanisms, and antimicrobial efficacy against multidrug-resistant and biofilm-associated pathogens. A range of nanocarriers, including chitosan, liposomes, nanobubbles, hybrid metal composites, metal–organic frameworks, and covalent organic frameworks, demonstrate improved microbial targeting, light activation efficiency, and therapeutic outcomes. Applications span wound healing, dental disinfection, food preservation, water treatment, and medical device sterilization. Conclusions and future directions are given, emphasizing the integration of smart nanocarriers and combinatorial therapies to enhance curcumin’s clinical translation. Full article
(This article belongs to the Topic Antimicrobial Agents and Nanomaterials—2nd Edition)
Show Figures

Figure 1

23 pages, 4165 KB  
Article
Structural and Functional Effects of the Interaction Between an Antimicrobial Peptide and Its Analogs with Model Bacterial and Erythrocyte Membranes
by Michele Lika Furuya, Gustavo Penteado Carretero, Marcelo Porto Bemquerer, Sumika Kiyota, Magali Aparecida Rodrigues, Tarcillo José de Nardi Gaziri, Norma Lucia Buritica Zuluaga, Danilo Kiyoshi Matsubara, Marcio Nardelli Wandermuren, Karin A. Riske, Hernan Chaimovich, Shirley Schreier and Iolanda Midea Cuccovia
Biomolecules 2025, 15(8), 1143; https://doi.org/10.3390/biom15081143 - 7 Aug 2025
Viewed by 438
Abstract
Antimicrobial peptides (AMPs) are a primary defense against pathogens. Here, we examined the interaction of two BP100 analogs, R2R5-BP100 (where Arg substitutes Lys 2 and 5) and R2R5-BP100-A-NH-C16 (where an Ala and a C [...] Read more.
Antimicrobial peptides (AMPs) are a primary defense against pathogens. Here, we examined the interaction of two BP100 analogs, R2R5-BP100 (where Arg substitutes Lys 2 and 5) and R2R5-BP100-A-NH-C16 (where an Ala and a C16 hydrocarbon chain are added to the R2R5-BP100 C-terminus), with membrane models. Large unilamellar vesicles (LUVs) and giant unilamellar vesicles (GUVs) were prepared with the major lipids in Gram-positive (GP) and Gram-negative (GN) bacteria, as well as red blood cells (RBCs). Fluorescence data, dynamic light scattering (DLS), and zeta potential measurements revealed that upon achieving electroneutrality through peptide binding, vesicle aggregation occurred. Circular dichroism (CD) spectra corroborated these observations, and upon vesicle binding, the peptides acquired α-helical conformation. The peptide concentration, producing a 50% release of carboxyfluorescein (C50) from LUVs, was similar for GP-LUVs. With GN and RBC-LUVs, C50 decreased in the following order: BP100 > R2R5-BP100 > R2R5BP100-A-NH-C16. Optical microscopy of GP-, GN-, and RBC-GUVs revealed the rupture or bursting of the two former membranes, consistent with a carpet mechanism of action. Using GUVs, we confirmed RBC aggregation by BP100 and R2R5-BP100. We determined the minimal inhibitory concentrations (MICs) of peptides for a GN bacterium (Escherichia coli (E. coli)) and two GP bacteria (two strains of Staphylococcus aureus (S. aureus) and one strain of Bacillus subtilis (B. subtilis)). The MICs for S. aureus were strain-dependent. These results demonstrate that Lys/Arg replacement can improve the parent peptide’s antimicrobial activity while increasing hydrophobicity renders the peptide less effective and more hemolytic. Full article
(This article belongs to the Topic Antimicrobial Agents and Nanomaterials—2nd Edition)
Show Figures

Graphical abstract

Back to TopTop